[go: up one dir, main page]

MX2017010359A - Cadena alfa del receptor de inmunoglobulina e (ige) de alta afinidad de fusion de fragmento cristalizable (fc). - Google Patents

Cadena alfa del receptor de inmunoglobulina e (ige) de alta afinidad de fusion de fragmento cristalizable (fc).

Info

Publication number
MX2017010359A
MX2017010359A MX2017010359A MX2017010359A MX2017010359A MX 2017010359 A MX2017010359 A MX 2017010359A MX 2017010359 A MX2017010359 A MX 2017010359A MX 2017010359 A MX2017010359 A MX 2017010359A MX 2017010359 A MX2017010359 A MX 2017010359A
Authority
MX
Mexico
Prior art keywords
chain
high affinity
affinity ige
ige receptor
fused high
Prior art date
Application number
MX2017010359A
Other languages
English (en)
Other versions
MX381726B (es
Inventor
Sakamoto Takashi
Inada Yoichi
Yokoyama Kazumasa
Original Assignee
Kissei Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56692248&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2017010359(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kissei Pharmaceutical filed Critical Kissei Pharmaceutical
Publication of MX2017010359A publication Critical patent/MX2017010359A/es
Publication of MX381726B publication Critical patent/MX381726B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Se proporciona una cadena a del receptor IgE de alta afinidad de fusión Fc con excelente estabilidad un bajo pH. Una proteína de fusión que comprende: (i) una cadena a del receptor IgE de alta afinidad; y ii) una región Fc de IgG1, en donde una región del fragmento enlazador entre el punto (i) y el punto (ii) es la secuencia de aminoácidos mostrada en SEC lD NO: 2.
MX2017010359A 2015-02-20 2016-02-19 Cadena alfa del receptor de inmunoglobulina e (ige) de alta afinidad de fusion de fragmento cristalizable (fc). MX381726B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2015032231 2015-02-20
JP2015252231 2015-12-24
PCT/JP2016/054854 WO2016133197A1 (ja) 2015-02-20 2016-02-19 Ｆｃ融合高親和性ＩｇＥ受容体α鎖

Publications (2)

Publication Number Publication Date
MX2017010359A true MX2017010359A (es) 2018-01-23
MX381726B MX381726B (es) 2025-03-13

Family

ID=56692248

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017010359A MX381726B (es) 2015-02-20 2016-02-19 Cadena alfa del receptor de inmunoglobulina e (ige) de alta afinidad de fusion de fragmento cristalizable (fc).

Country Status (18)

Country Link
US (2) US10077297B2 (es)
EP (1) EP3260469B1 (es)
JP (1) JP6192862B2 (es)
KR (2) KR20230132610A (es)
CN (1) CN107207623B (es)
AU (1) AU2016220766B2 (es)
BR (1) BR112017017609A2 (es)
CA (1) CA2976623C (es)
ES (1) ES2806205T3 (es)
IL (1) IL253832B (es)
MX (1) MX381726B (es)
PL (1) PL3260469T3 (es)
PT (1) PT3260469T (es)
RU (1) RU2715606C2 (es)
SG (1) SG11201706543UA (es)
TW (1) TWI691512B (es)
WO (1) WO2016133197A1 (es)
ZA (2) ZA201706281B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7127859B2 (ja) * 2016-11-09 2022-08-30 ノース カロライナ ステート ユニバーシティ キメラタンパク質を用いたアレルギー疾患の治療
KR102038672B1 (ko) * 2018-01-08 2019-10-30 (주)지아이이노베이션 IgE Fc 수용체의 알파 서브유닛의 세포외 도메인을 포함하는 약학적 조성물
US12410233B2 (en) * 2018-01-08 2025-09-09 Gi Innovation, Inc. Extracellular domain of alpha subunit of IgE Fc receptor, pharmaceutical composition comprising same and method for producing same
JP7041272B2 (ja) * 2018-01-12 2022-03-23 ジーアイ・イノベイション・インコーポレイテッド プロバイオティクスおよびＩｇＥへの結合親和性を有するポリペプチドを含む組成物およびその使用
WO2019183437A1 (en) 2018-03-23 2019-09-26 North Carolina State University Methods and compositions for antibody to high affinity receptor for ige
PE20220098A1 (es) * 2019-07-08 2022-01-24 Gi Innovation Inc Dimero polipeptido con alto contenido en acido sialico, que comprende el dominio extracelular de la subunidad alfa del receptor fc de ige, y composicion farmaceutica que comprende el mismo
WO2021006603A1 (ko) * 2019-07-08 2021-01-14 주식회사 프로젠 신규 알러지 질환 치료용 약학적 조성물
WO2021006375A1 (ko) * 2019-07-08 2021-01-14 (주)지아이이노베이션 Ige fc 수용체의 알파 서브유닛의 세포외 도메인을 포함하는 시알산 함량이 높은 폴리펩티드 이량체 및 이를 포함하는 약학적 조성물

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
US5641870A (en) * 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
ATE542137T1 (de) * 2001-12-04 2012-02-15 Merck Patent Gmbh Immunocytokine mit modulierter selektivität
WO2008028068A2 (en) 2006-08-30 2008-03-06 Genentech, Inc. NON-HUMAN PRIMATE FCεR1α POLYPEPTIDES
US20110212084A1 (en) * 2007-02-15 2011-09-01 Astrazeneca Ab Binding members for ige molecules
AR065368A1 (es) 2007-02-15 2009-06-03 Astrazeneca Ab Anticuerpos para moleculas de ige
TWI464178B (zh) * 2007-03-22 2014-12-11 Genentech Inc 細胞凋亡抗-ｉｇｅ抗體
KR101631454B1 (ko) 2008-10-31 2016-06-17 가부시키가이샤 한도오따이 에네루기 켄큐쇼 논리회로
CN101633698B (zh) 2009-08-26 2011-12-21 北京精益泰翔技术发展有限公司 一种免疫融合蛋白及其编码基因与应用
NZ599600A (en) 2009-10-26 2015-04-24 Genentech Inc Assays for detecting antibodies specific to therapeutic anti-ige antibodies and their use in anaphylaxis
SMT202000572T1 (it) * 2010-02-19 2021-01-05 Xencor Inc Nuove immunoadesine ctla4-ig
GB201014033D0 (en) * 2010-08-20 2010-10-06 Ucb Pharma Sa Biological products
WO2012169735A2 (ko) 2011-06-07 2012-12-13 (주)네오팜 FCεRI의 수용성 단편을 포함하는 복합체 및 이를 포함하는 IGE 매개 알레르기성 질환 치료용 조성물
GB201203051D0 (en) * 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
GB201203071D0 (en) * 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
WO2014087010A1 (en) * 2012-12-07 2014-06-12 Ablynx N.V. IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE

Also Published As

Publication number Publication date
MX381726B (es) 2025-03-13
CN107207623A (zh) 2017-09-26
CN107207623B (zh) 2021-01-29
ZA201804191B (en) 2019-09-25
NZ734482A (en) 2022-03-25
SG11201706543UA (en) 2017-09-28
PL3260469T3 (pl) 2020-11-02
US10077297B2 (en) 2018-09-18
KR20230132610A (ko) 2023-09-15
RU2017132689A3 (es) 2019-08-15
CA2976623A1 (en) 2016-08-25
KR20170120579A (ko) 2017-10-31
EP3260469A4 (en) 2018-08-22
TWI691512B (zh) 2020-04-21
US20180044402A1 (en) 2018-02-15
AU2016220766A1 (en) 2017-08-31
WO2016133197A1 (ja) 2016-08-25
TW201636373A (zh) 2016-10-16
JPWO2016133197A1 (ja) 2017-06-15
AU2016220766B2 (en) 2021-03-04
US20180312566A1 (en) 2018-11-01
PT3260469T (pt) 2020-07-29
KR102602539B1 (ko) 2023-11-15
RU2715606C2 (ru) 2020-03-02
IL253832B (en) 2021-05-31
RU2017132689A (ru) 2019-03-20
ES2806205T3 (es) 2021-02-16
JP6192862B2 (ja) 2017-09-06
HK1244016A1 (zh) 2018-07-27
EP3260469A1 (en) 2017-12-27
IL253832A0 (en) 2017-09-28
ZA201706281B (en) 2019-04-24
CA2976623C (en) 2023-03-21
BR112017017609A2 (pt) 2018-05-08
EP3260469B1 (en) 2020-05-13

Similar Documents

Publication Publication Date Title
MX2017010359A (es) Cadena alfa del receptor de inmunoglobulina e (ige) de alta afinidad de fusion de fragmento cristalizable (fc).
CL2018003148A1 (es) Proteínas de fusión y usos de las mismas.
CY1124309T1 (el) Τροποποιημενα πολυπεπτιδια fgf-21 και χρησεις εξ αυτων
MX2023008559A (es) Proteínas de fusión fc heterodiméricas il15/il15ra.
CL2017001070A1 (es) Variantes de interferon a2b
CO2017002166A2 (es) Proteínas de fusión de interleucina 2 / receptor de interleucina-2 alfa
UY36304A (es) Proteínas de fusión, bacterias recombinantes y métodos de uso de las bacterias recombinantes
ES2676499T3 (es) Proteínas de fusión Fc que comprenden nuevos enlazadores o disposiciones
MX2014005108A (es) Constructos de polipeptidos y sus usos.
MX2017006866A (es) Pares de unión para producción de péptidos.
MY204756A (en) Factor viii chimeric proteins and uses thereof
PE20091004A1 (es) Proteinas de union a antigenos c-fms humanos
PE20170665A1 (es) Anticuerpos anti-tau humanizados
MX382929B (es) Polipéptido heterodimerizado.
AR083454A1 (es) Antigeno de citomegalovirus
ES2721309T3 (es) Composición para preparar tagatosa y método para preparar tagatosa a partir de fructosa
AR075029A1 (es) Metodo para producir una proteina o un peptido fisiologicamente activo usando un fragmento de inmunoglobulina
MX387560B (es) Procedimiento para mejorar la solubilidad de proteínas y péptidos usando un enlace del fragmento fc de inmunoglobulina.
MX2020006635A (es) Proteína de fusión enzimática terapéutica que tiene una nueva estructura y uso de la misma.
ES2572215T3 (es) Anticuerpo neutralizante contra el receptor de prolactina Mat3 y su uso terapéutico
MX2017007105A (es) Variantes de lipasa y polinucleotidos que las codifican.
EA201691532A1 (ru) Сверхэкспрессия регуляторов пути n-гликозилирования для модуляции гликозилирования рекомбинантных белков
WO2018069947A8 (en) Nucleotide sequence expressing an exosome-anchoring protein for use as vaccine
MX2018013177A (es) Proteina de fusion que contiene variante ccl3 y uso de la misma referencia cruzada para aplicaciones relacionadas.
AR110908A1 (es) Constructo promotor para la síntesis de proteínas libre de células